We are analyzing https://link.springer.com/article/10.1007/s00262-007-0291-6.

Title:
The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses | Cancer Immunology, Immunotherapy
Description:
Blockade of CTLA-4 by monoclonal antibodies (mAb) can mediate regression of tumors and increase the efficacy of tumor antigen specific vaccines. Blockade of CTLA-4 has also been shown to significantly increase the avidity of antigen-specific T cells after immunization with live recombinant viral vector based vaccine. Here, we demonstrate a biological synergy between CTLA-4 blockade and active vaccine therapy consisting of recombinant vaccinia and avipox viruses expressing carcinoembryonic antigen (CEA) and three T cell costimulatory molecules to enhance antitumor effects. However, this synergy was very much dependent on the temporal relationship of scheduling of the two agents. We evaluated the strategies in both a foreign antigen model using β-galactosidase as immunogen, and in a “self” antigen model using CEA as immunogen. For antitumor activity the model used consisted of mice transgenic for human CEA and a murine carcinoma cell line transfected with CEA. The enhanced antitumor activity after vaccine and CTLA-4 blockade did not result in any signs of autoimmunity. These studies form a rational basis for the use of vector-based vaccines with anti-CTLA-4 and demonstrate that both enhancement of positive costimulatory signals and inhibition of negative costimulatory signals can be simultaneously exploited. These studies also underscore the importance of “drug” scheduling in vaccine combination therapies.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

google, scholar, pubmed, cas, article, cancer, ctla, antigen, blockade, schlom, antitumor, immunol, cytotoxic, res, vaccine, responses, allison, immunotherapy, costimulatory, hodge, cells, recombinant, cell, immunity, lymphocyteassociated, melanoma, research, tcell, tumor, model, combination, exp, med, enhances, vaccines, cea, access, antibody, treatment, abrams, hurwitz, privacy, cookies, content, signals, chakraborty, therapy, carcinoembryonic, activity, human,

Topics {✒️}

granulocyte/macrophage colony-stimulating factor vaccine-mediated t-cell killing vaccine-mediated t-cell responses month download article/chapter amplify t-cell activation antitumor t-cell responses enhance t-cell immunity ccr8/ctla-4 bispecific antibody restricted tumor-bearing stages anti-neoplastic agents enhances related subjects ctla-4-mediated inhibitory signals guevara-patino ja class ii-restricted peptides vector-based vaccines recombinant vaccinia-cea virus diversified subcutaneous/intratumoral vaccination antibody-mediated effects full article pdf article cancer immunology recombinant vaccinia virus dendritic cell vaccine privacy choices/manage cookies targeted antibody therapies transplanted ct26 tumour cell costimulatory molecules antigen-specific cd8+ cytotoxic positive costimulatory signals positive selecting peptide multiple melanoma peptides van der putten van duivenvoorde lm experimental mammary carcinoma intramural research program blockade enhances incidence negative costimulatory signals resected stages iii vaccine combination therapies article chakraborty negative costimulatory signal costimulatory molecules synergize ctla-4 blockade enhances van elsas immunotherapy article enhance antitumor effects european economic area mathematical modelling tool melanocyte differentiation proteins kudo-saito regional lymph nodes

Questions {❓}

Allison JP, Chambers C, Hurwitz A, Sullivan T, Boitel B, Fournier S et al (1998) A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance?
Pardoll D (2003) Does the immune system see tumors as foreign or self?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses
         description:Blockade of CTLA-4 by monoclonal antibodies (mAb) can mediate regression of tumors and increase the efficacy of tumor antigen specific vaccines. Blockade of CTLA-4 has also been shown to significantly increase the avidity of antigen-specific T cells after immunization with live recombinant viral vector based vaccine. Here, we demonstrate a biological synergy between CTLA-4 blockade and active vaccine therapy consisting of recombinant vaccinia and avipox viruses expressing carcinoembryonic antigen (CEA) and three T cell costimulatory molecules to enhance antitumor effects. However, this synergy was very much dependent on the temporal relationship of scheduling of the two agents. We evaluated the strategies in both a foreign antigen model using β-galactosidase as immunogen, and in a “self” antigen model using CEA as immunogen. For antitumor activity the model used consisted of mice transgenic for human CEA and a murine carcinoma cell line transfected with CEA. The enhanced antitumor activity after vaccine and CTLA-4 blockade did not result in any signs of autoimmunity. These studies form a rational basis for the use of vector-based vaccines with anti-CTLA-4 and demonstrate that both enhancement of positive costimulatory signals and inhibition of negative costimulatory signals can be simultaneously exploited. These studies also underscore the importance of “drug” scheduling in vaccine combination therapies.
         datePublished:2007-02-23T00:00:00Z
         dateModified:2007-02-23T00:00:00Z
         pageStart:1471
         pageEnd:1484
         sameAs:https://doi.org/10.1007/s00262-007-0291-6
         keywords:
            CTLA-4
            Costimulation
            Vaccine
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0291-6/MediaObjects/262_2007_291_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0291-6/MediaObjects/262_2007_291_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0291-6/MediaObjects/262_2007_291_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0291-6/MediaObjects/262_2007_291_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0291-6/MediaObjects/262_2007_291_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0291-6/MediaObjects/262_2007_291_Fig6_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:56
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Mala Chakraborty
               affiliation:
                     name:National Institutes of Health
                     address:
                        name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jeffrey Schlom
               affiliation:
                     name:National Institutes of Health
                     address:
                        name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:James W. Hodge
               affiliation:
                     name:National Institutes of Health
                     address:
                        name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses
      description:Blockade of CTLA-4 by monoclonal antibodies (mAb) can mediate regression of tumors and increase the efficacy of tumor antigen specific vaccines. Blockade of CTLA-4 has also been shown to significantly increase the avidity of antigen-specific T cells after immunization with live recombinant viral vector based vaccine. Here, we demonstrate a biological synergy between CTLA-4 blockade and active vaccine therapy consisting of recombinant vaccinia and avipox viruses expressing carcinoembryonic antigen (CEA) and three T cell costimulatory molecules to enhance antitumor effects. However, this synergy was very much dependent on the temporal relationship of scheduling of the two agents. We evaluated the strategies in both a foreign antigen model using β-galactosidase as immunogen, and in a “self” antigen model using CEA as immunogen. For antitumor activity the model used consisted of mice transgenic for human CEA and a murine carcinoma cell line transfected with CEA. The enhanced antitumor activity after vaccine and CTLA-4 blockade did not result in any signs of autoimmunity. These studies form a rational basis for the use of vector-based vaccines with anti-CTLA-4 and demonstrate that both enhancement of positive costimulatory signals and inhibition of negative costimulatory signals can be simultaneously exploited. These studies also underscore the importance of “drug” scheduling in vaccine combination therapies.
      datePublished:2007-02-23T00:00:00Z
      dateModified:2007-02-23T00:00:00Z
      pageStart:1471
      pageEnd:1484
      sameAs:https://doi.org/10.1007/s00262-007-0291-6
      keywords:
         CTLA-4
         Costimulation
         Vaccine
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0291-6/MediaObjects/262_2007_291_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0291-6/MediaObjects/262_2007_291_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0291-6/MediaObjects/262_2007_291_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0291-6/MediaObjects/262_2007_291_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0291-6/MediaObjects/262_2007_291_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0291-6/MediaObjects/262_2007_291_Fig6_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:56
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Mala Chakraborty
            affiliation:
                  name:National Institutes of Health
                  address:
                     name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jeffrey Schlom
            affiliation:
                  name:National Institutes of Health
                  address:
                     name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:James W. Hodge
            affiliation:
                  name:National Institutes of Health
                  address:
                     name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:56
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:National Institutes of Health
      address:
         name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
         type:PostalAddress
      name:National Institutes of Health
      address:
         name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
         type:PostalAddress
      name:National Institutes of Health
      address:
         name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Mala Chakraborty
      affiliation:
            name:National Institutes of Health
            address:
               name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
               type:PostalAddress
            type:Organization
      name:Jeffrey Schlom
      affiliation:
            name:National Institutes of Health
            address:
               name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:James W. Hodge
      affiliation:
            name:National Institutes of Health
            address:
               name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
      name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
      name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(149)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.83s.

LINK . SPRINGER . COM {}